title: Improving psychiatric drug benefit management: II. Kaiser Permanente's approach to SSRIs.
authors.affiliation: Department of Ambulatory Care and Preventiom, Boston, Massachusetts 02215, USA. jim_sabin@hphc.org
authors.forename: James E
authors.initials: JE
authors.lastname: Sabin
authors.forename: Norman
authors.initials: N
authors.lastname: Daniels
mesh_terms: D017046:Cost Savings; D003866:Depressive Disorder / Q000188:drug therapy* / Q000191:economics*; D016527:Drug Costs / Q000706:statistics & numerical data*; D016568:Drugs, Generic / Q000191:economics* / Q000627:therapeutic use; D005473:Fluoxetine / Q000191:economics / Q000627:therapeutic use; D006279:Health Maintenance Organizations / Q000191:economics*; D006801:Humans; D007356:Insurance, Pharmaceutical Services / Q000191:economics*; D008329:Managed Care Programs / Q000191:economics*; D017367:Selective Serotonin Reuptake Inhibitors / Q000191:economics* / Q000627:therapeutic use; D014481:United States
chemical_list: D016568:Drugs, Generic; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors